Xu Hui, Wang Chao, Song Ting-Ting, Liu Yang, Dong Chang-Wu
Anhui University of Chinese Medicine, Hefei 230012, China.
The Second Affiliated Hospital of Anhui University of Chinese Medicine, Hefei 230001, China.
Evid Based Complement Alternat Med. 2022 Nov 7;2022:6088673. doi: 10.1155/2022/6088673. eCollection 2022.
The aim of the study is to explore the effects and mechanisms of action of Ziyin Qianyang Formula (ZYQYF) on renal fibrosis in spontaneously hypertensive rats (SHRs).
Forty SHRs were randomly divided into a model group, Ziyin Qianyang Formula regular-dose and high-dose groups (ZYQYF-R, 20 g/kg; ZYQYF-H, 40 g/kg), and a western medicine group (enalapril 10 mg/kg), and 10 Sprague-Dawley rats were selected as the normal group. The rats received continuous gavage administration for 6 weeks and systolic blood pressure (SBP) measurements were obtained every fortnight. The serum levels of urea, serum creatinine (sCr), and uric acid (UA) were measured; the pathological morphology and collagen content of the kidneys were observed by hematoxylin-eosin (HE) and Masson staining; and the serum Ang II level was measured by an enzyme-linked immunosorbent assay (ELISA). Transforming growth factor (TGF)-1, Smad-2, Smad-3, and Smad-7 protein and mRNA expressions in kidney tissues was evaluated by western blotting and reverse transcription-polymerase chain reaction.
The ZYQYF-H group showed significantly a lower renal weight and renal weight/body weight than the model group. The enalapril and ZYQYF-H groups showed significantly lower SBP than other groups after 6 weeks of administration. The ZYQYF-H group showed better improvement than the ZYQYF-R and enalapril groups in glomerular and tubular morphology and better reductions in inflammatory cell infiltration and collagen volumetric fraction. The ZYQYF-H group also showed better reductions in serum UA and Ang II levels; collagen-I, collagen-III, and p-Smad2/Smad-2 protein expression; and Smad-2 mRNA expression and a better increase in Smad-7 protein and mRNA expression than the enalapril group. Besides, the degree of renal function and fibrosis improvement was positively correlated with the dose of ZYQYF.
ZYQYF can significantly reduce SHR blood pressure, protect renal function and structure, and improve renal fibrosis by regulating Smad proteins through TGF-1.
本研究旨在探讨滋阴潜阳方(ZYQYF)对自发性高血压大鼠(SHRs)肾纤维化的影响及作用机制。
将40只SHRs随机分为模型组、滋阴潜阳方常规剂量组和高剂量组(ZYQYF-R,20 g/kg;ZYQYF-H,40 g/kg)以及西药组(依那普利10 mg/kg),选取10只Sprague-Dawley大鼠作为正常组。大鼠连续灌胃给药6周,每两周测量一次收缩压(SBP)。检测血清尿素、血清肌酐(sCr)和尿酸(UA)水平;通过苏木精-伊红(HE)和Masson染色观察肾脏的病理形态和胶原含量;采用酶联免疫吸附测定(ELISA)法检测血清血管紧张素II(Ang II)水平。通过蛋白质印迹法和逆转录-聚合酶链反应评估肾组织中转化生长因子(TGF)-1、Smad-2、Smad-3和Smad-7蛋白及mRNA表达。
ZYQYF-H组的肾脏重量和肾脏重量/体重显著低于模型组。给药6周后,依那普利组和ZYQYF-H组的SBP显著低于其他组。ZYQYF-H组在肾小球和肾小管形态方面的改善优于ZYQYF-R组和依那普利组,炎症细胞浸润和胶原体积分数降低更明显。ZYQYF-H组的血清UA和Ang II水平降低幅度也更大;I型胶原、III型胶原和p-Smad2/Smad-2蛋白表达以及Smad-2 mRNA表达降低幅度更大,Smad-7蛋白和mRNA表达增加幅度优于依那普利组。此外,肾功能和纤维化改善程度与ZYQYF剂量呈正相关。
ZYQYF可通过TGF-1调节Smad蛋白,显著降低SHRs血压,保护肾功能和结构,改善肾纤维化。